Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neridronate in Complex Regional Pain Syndrome Type 1
NCT07210515Phase 3Recruiting
- Sponsor
- Ambros Therapeutics
- Start
- Apr 2026
- Primary completion
- Dec 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial in Complex Regional Pain Syndrome Type 1 (CRPS-1) comparing neridronate with Placebo (2 arms). Primary endpoint: Change in pain intensity at 12 weeks. Started Apr 2026; status: recruiting.
02
Drugs
neridronic acid
03
Conditions
Complex Regional Pain Syndrome Type 1 (CRPS-1)
Beyond the preview
Go deeper on NCT07210515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07210515.